Editorial Policies

Focus and Scope

Progress in Drug Discovery & Biomedical Science (PDDBS) is an open access journal dedicated to the exchange of information and understandings about the research in areas of drug discovery and biomedical science based on the principles established through international conventions.

PDDBS covering both the fundamental and application aspects of drug discovery & biomedical science and welcoming papers having a good interdisciplinary approach.

Coverage includes:

-Plant, microbes bioactives

-Basic or applied biomedical research

-Toxicology & pharmacology

- Molecular/cell biology

- Drug delivery

- Therapeutic strategies/targets

- ADME

- Clinical trials

- Structural Biology and Biomolecular Modeling

- Curriculum, instruction and pedagogy

 

Section Policies

ORIGINAL RESEARCH ARTICLES

Original Research Articles should contain all reports of original research in Progress in Drug Discovery & Biomedical Science. This main mode of scientific communication should consist of principal research governing major contributions to the various field. The report may contain significant findings, latest methodologies, statistical studies and proper evidence of conclusions.

Checked Open Submissions Checked Indexed Checked Peer Reviewed

REVIEW ARTICLES

Reviews describe as of the latest findings, significant new development and progress, compilation of published evidence of the analysis at particular subject area of research under this Journal's scope.

Checked Open Submissions Checked Indexed Checked Peer Reviewed

EDITORIAL

Editorial presents the opinion of an article or specific topic related to drug discovery and biomedical science. It also includes announcements, highlighting recent changes in accordance to the journal.

Checked Open Submissions Checked Indexed Checked Peer Reviewed

CASE REPORTS

Case report provide detailed reports of symptoms, diagnosis, treatment and modification techniques in methodology with 2 or 3 clinical cases.

Checked Open Submissions Checked Indexed Checked Peer Reviewed

CORRESPONDENCE ARTICLE

Correspondences is Letters to the Editor, Responses, Short Comment from the authors for certain issues. They are not peer-reviewed and should not contain more than 10 references.

Checked Open Submissions Checked Indexed Checked Peer Reviewed

GENOME REPORT

Genome report format publishes short manuscripts announcing the availability of recently sequenced genomes of prokaryotic and eukaryotic microbes and viruses in the public databases. These announcements inform readers of the availability of new genome sequences and provide the rationale for sequencing a particular organism, as well as particulars of the protocols used in assembly of the genome sequence. Manuscripts submitted to genome report will be editorially reviewed for appropriate content; submissions will be accepted and published at the editor's discretion.

Checked Open Submissions Checked Indexed Checked Peer Reviewed

METHODS ARTICLE

Methods articles present a new method, or emerging technique, or existing known method with detailed optimization steps involved that opens new avenues or providing a good standardization for the investigation of important issues in a field. Method articles should include:

- objectives and validation of the method with a detailed protocol;

- example(s) of its application and effectiveness;

- advantages and limitations.

Checked Open Submissions Checked Indexed Checked Peer Reviewed

CURRICULUM, INSTRUCTION AND PEDAGOGY

Curriculum, Instruction, and Pedagogy  articles describe innovation in curricula, courses, teaching methodologies, teaching formats, educational training programs, pedagogical frameworks such as competency models, evaluation techniques, instructions on data analysis or data collection methods, and other innovative pedagogical elements. 

Checked Open Submissions Checked Indexed Checked Peer Reviewed
 

Publication Frequency

The publication frequency of Progress in Drug Discovery and Biomedical Science is annually.

 

Open Access Policy

Progress in Drug Discovery and Biomedical Science is a Gold Open access journal. Author(s) shall retain the copyright of their work, but grant to the Publisher a license to publish.

Progress in Drug Discovery and Biomedical Science works under the license of Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) that allows copying, distribution, and transmission of the published work with the acknowledgement of original creator. This broad license intends to facilitate free access to, as well as the unrestricted reuse of, original works of all types.

 

Code of Ethics

1) HH Publisher adhere to the Code of Conduct for Publishers.

2) Editors obliged to Code of Conduct for Journal Editors.

Committee on Publication Ethics (COPE)

HH Publisher also ensures the legitimacy of this journal by practising to be transparent to the authors and researchers in accordance to the Principles of Transparency and Best Practice in Scholarly Publishing.

 

*All relevant complaints may direct to the Editor office and the journal editorial team will addressed the complaint according to the Publishing procedure and protocol.

 

Editorial Policies

A manuscript would not be accepted if it has been published or is currently under consideration for publication in any other journals. The author will need to notify the editorial team if the data in their submission has been presented in conferences.

After acceptance, the Publisher will have the right to edit the work for the original edition and for any revision.

 

Plagiarism

The editorial team does not permit of any plagiarism attempts in the manuscript. Each manuscripts submitted will undergo primary screening of originality through iThenticate. If plagiarism is detected, editor will run through the severity of plagiarism and the manuscript will be rejected if the rate of plagiarism is high depending on editorial decision. Therefore, if a manuscript uses a text copied directly from another source, this text must be written in quotation marks and the original source must be cited.

 

Authorship

Authorship should be limited to people who have contributed substantially to the work. Authors must indicate their specific contributions to the published work. This information should be listed in the manuscript under the section ‘Author Contribution’. Examples of contributions include: designed research, performed research, contributed new reagents or analytic tools, analyzed data, wrote the paper.

For more information on submission’s format, please refer to the ‘Author Guidelines’ link accessible from the ‘About’ button at the top row of this page.

The corresponding author should be clearly indicated for all manuscripts submitted. A maximum of two corresponding authors are allowed for the responsibilities associated. The corresponding author(s) is responsible for:

  • Obtaining permission from all the authors mentioned in the manuscript
  • Ensuring adherence to all editorial and submission policies and for any communications and actions that may be necessary after publication
  • Including written permission from the authors of the work concerned for any mention of any unpublished material included in the manuscript, e.g. data from manuscripts-in-press, personal communication, or work in preparation.

 

Permission and Reprints

Any part of materials published in Progress in Drug Discovery & Biomedical Science may not be reproduced without written permission of the publisher. Please click HERE to write in the permission request.

 

Advertising Policies

  1. All advertisements, exhibition or sales are subject to approval of the Publisher which reserves the right to reject or cancel any advertisement at any time.
  2. Advertisers and sponsors have no rights or knowledge on editorial content, decisions or judgment. Editors have no rights and knowledge on advertisement, exhibition or sales. Both advertisement and editorial have been conducted by separate department.
  3. Advertisements or sponsored content will be easily distinguished with the editorial content on the website.
  4. Advertisement products must comply with the relevant laws and regulations in the country/geographic area where the advertisement appears. Advertisements for pharmaceutical products (including new product applications) that are subject to US Food and Drug Administration (FDA) oversight must comply with FDA regulations regarding advertising and promotion.
  5. Publisher will provide google analytics to the advertiser after the ads discontinue.

Further inquiries and purchasing ad space, please contact us.